BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co Shareholder Yield

The Shareholder Yield of BrightGene Bio-Medical Technology Co (688166.SS) as of Nov 22, 2026 is 0.61 %. In the previous year, Shareholder Yield was 0.71 % — a change of -13.36% (lower).

Shareholder Yield

0.61 %

YoY

-13.36%

Last updated:

Shareholder Yield of BrightGene Bio-Medical Technology Co is 2025 0.61 % . Shareholder Yield of BrightGene Bio-Medical Technology Co was 2024 0.71 % . It decreases by -13.36% lower compared to the previous year.

The BrightGene Bio-Medical Technology Co Shareholder Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Shareholder Yield
Date
Shareholder Yield
Jan 1, 2018
0.18 CNY
Jan 1, 2019
0.18 CNY
Jan 1, 2020
0.18 CNY
Jan 1, 2021
0.28 CNY
Jan 1, 2022
0.52 CNY
Jan 1, 2023
0.59 CNY
Jan 1, 2024
0.71 CNY
Jan 1, 2025
0.61 CNY
The BrightGene Bio-Medical Technology Co Shareholder Yield history
YEARShareholder YieldYoY
0.61 %-13.36%
0.71 %+19.33%
0.59 %+13.64%
0.52 %+84.34%
0.28 %+53.39%
0.18 %0.00%
0.18 %0.00%
0.18 %+1,728.33%
0.01 %-44.50%
0.02 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

Shareholder Yield of BrightGene Bio-Medical Technology Co is 0.61 % in 2025.

Shareholder Yield of BrightGene Bio-Medical Technology Co changed from 0.71 % to 0.61 %, representing a -13.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Shareholder Yield BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

Shareholder yield combines dividend yield and buyback yield to show the total cash return to shareholders. It captures both dividends and share repurchases.

To evaluate Shareholder Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Shareholder Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Shareholder Yield's BrightGene Bio-Medical Technology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — BrightGene Bio-Medical Technology Co

All Key Metrics — BrightGene Bio-Medical Technology Co